Physician

Eric Dean Mininberg, M.D.

According to 2025 Medicare claims, Eric Mininberg, M.D. (NPI: 1275591067) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Fulton, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30318-0922.

Mininberg's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 577 traditional Medicare patients, billed 118,845 HCPCS/CPT codes, and received $2,351,111 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,157 prescription claims across 356 beneficiaries totaling $5,542,713 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 75 claims. Open Payments data shows 12 records totaling $250. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,392,565 to $2,351,111. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $486,567 to $5,542,713. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $2,300 to $7,747.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	688	86,674	$1,392,565
2016	704	89,238	$1,642,849
2017	707	86,594	$1,408,237
2018	719	95,264	$1,627,199
2019	703	110,821	$1,826,580
2020	639	95,007	$1,951,914
2021	602	116,926	$2,175,938
2022	568	115,730	$2,330,837
2023	597	122,493	$2,593,869
2024	577	118,845	$2,351,111

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	202	1,394	$486,567
2016	244	1,541	$649,056
2017	249	1,655	$990,411
2018	243	1,467	$1,225,571
2019	262	1,558	$2,146,427
2020	300	1,784	$3,488,307
2021	312	1,838	$4,157,879
2022	314	1,822	$3,809,044
2023	338	1,906	$4,787,016
2024	356	2,157	$5,542,713

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	93	$15,865
2016	N/R	87	$17,996
2017	N/R	45	$8,604
2018	N/R	25	$1,337
2019	N/R	33	$1,430
2020	N/R	87	$5,263
2021	N/R	33	$771
2022	N/R	35	$1,499
2023	N/R	75	$35,097
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	59	292	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	215	438	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	306	464	$58
96372	Injection of drug or substance under skin or into muscle	66	175	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	370	831	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	73	2,044	$1,320,980
Imbruvica	Ibrutinib	40	1,106	$1,002,192
Pomalyst	Pomalidomide	25	700	$572,992
Calquence	Acalabrutinib Maleate	30	900	$386,924
Tagrisso	Osimertinib Mesylate	23	690	$369,668

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$250	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Eric Dean Mininberg, M.D.?

Tedicare shows public-source Medicare data for Eric Dean Mininberg, M.D. (NPI 1275591067), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eric Dean Mininberg, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eric Dean Mininberg, M.D.?

Eric Dean Mininberg, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Eric Dean Mininberg, M.D. have Open Payments data?

Eric Dean Mininberg, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.